.svg)
.svg){kind=logo}
.svg){kind=logo}
.svg)
About Us
Precision Care that Preserves Dignity: Innovation in Prostate Health
Focalyx is a novel method for the treatment of Prostate Cancer that allows to eliminate the cancerous lesions preserving the prostate and therefore the physical integrity of the patient, which enables him to overcome the cancer, maintaining his dignity and quality of life.
We collaborate with innovative healthcare teams to reimagine care and make it:
More Accessible
More Affordable
More Human
Our Focus
Early detection
Less Invasive Approach
Efficient treatment
Faster Recovery to Return to a Full Life
Our Purpose
Preserving the physical integrity of the patient and is our top priority
This is done by mapping out where their cancerous lesions are and eradicating ONLY this region, sparing all healthy tissue and thus improving our patients’ urinary and sexual function.
46 Doctors
Doctors using focalyx
7 Patients
patients per week
20 Countries
How many countries
Founder
Dr. Alessandra Pluchino
COO
An MD/PhD with extensive experience in the medical device industry, Dr. Pluchino oversees the operational aspects of Focalyx®.
Dr. Fernando Bianco
Founder and CEO
A board-certified urologist and oncologist with over 20 years of experience in major U.S. hospitals.
Dr. Bianco pioneered the Focalyx® paradigm of MR Fusion procedures for the prostate gland in office settings. He completed his medical degree at the Universidad Central de Venezuela and his Urology Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York City.
Dr. Alessandra Pluchino
COO
An MD/PhD with extensive experience in the medical device industry, Dr. Pluchino oversees the operational aspects of Focalyx®.
.svg){kind=icon}
.svg){kind=icon}
Our History
For over two decades, Focalyx has pioneered innovative prostate cancer treatments, focusing on precision, minimally invasive procedures, and improved patient outcomes
1998-2005
Dr. Fernando Bianco
Is a resident/fellow in urology, as he witnesses horror story after horror story of men being castrated for something that could be ameliorated.
2006-2015
Focal therapy starts to get some traction
As a number of methodologies and devices are coming about, but many still possess flaws. Urologists around the world struggle with transrectal approaches, continued patient incontinence and general inaccuracy.
2016-2018
Smart Target technology
Gets developed in University of College London. Dr. Bianco, along with many of his expert colleagues in focal therapy, witnesses this groundbreaking software and insists on bringing it abroad. This is when Dr. Bianco started his data collection efforts to prove the outcomes.
2019-2024
SmartTarget gets rebranded
Under Focalyx Fusion, with a bounty of urologists around the world using it and contributing to a 5-year study proving that this not only betters the doctor’s ability to remove the cancer, but it shows groundbreaking evidence in improving urinary incontinence and sexual function.
2025+
MOre updates
With more updates and devices in the works, Focalyx continues to push the envelope on what is possible in men’s health.
